<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00993070</url>
  </required_header>
  <id_info>
    <org_study_id>MTU-I-1-45/52</org_study_id>
    <nct_id>NCT00993070</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of Topical Capsaicin in Painful Diabetic Neuropathy</brief_title>
  <official_title>A Randomized, Crossover, Double Blinded, Placebo Controlled Trial of Topical Capsaicin in Treatment of Painful Diabetic Neuropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thammasat University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bangkok Drug company</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Thammasat University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Painful diabetic neuropathy is the most common cause of neuropathic pain. 0.075% topical
      capsaicin has been used to treat the pain, but there is no data in lower concentration. This
      is the efficacy and safety of 0.025% topical capsaicin in treatment of painful diabetic
      polyneuropathy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patient is randomized to receive either 0.025% topical capsaicin or vehicle control (placebo)
      for 8 weeks. After one week wash-out period, patients will be switched to the other group for
      8 weeks.

      Outcome will be assessed by visual analog scale, neuropathic pain scale, SF-MPQ, SF-36.
      Safety and tolerability will be recorded.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain relief from pain score reduction, using visual analog scale (VAS)</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall clinical improvement, measured by Clinician Global Impression of Change(CGIC)</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Diabetic Polyneuropathy</condition>
  <arm_group>
    <arm_group_label>Capsaicin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capsaicin</intervention_name>
    <description>0.025% topical capsaicin applied 4 times per day for 8 weeks</description>
    <arm_group_label>Capsaicin</arm_group_label>
    <other_name>Capsika gel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>vehicle gel, applied 4 times per day for 8 weeks</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  History of type 2 Diabetes mellitus

          -  Peripheral neuropathy

          -  Stabilized on pain medication for at least one month

          -  No previous invasive intervention for pain relief

        Exclusion Criteria:

          -  Local wound or skin abnormality in the applicable area

          -  Allergic to capsaicin

          -  Refuse to participate or give consent

          -  Has other significant disease or receive medication that may worsen neuropathy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kongkiat Kulkantrakorn, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Thammasat University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Thammasat University Hospital</name>
      <address>
        <city>Pathumthani</city>
        <zip>12120</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 7, 2009</study_first_submitted>
  <study_first_submitted_qc>October 8, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 9, 2009</study_first_posted>
  <last_update_submitted>May 8, 2012</last_update_submitted>
  <last_update_submitted_qc>May 8, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 9, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Thammasat University</investigator_affiliation>
    <investigator_full_name>Kongkiat Kulkantrakorn</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>capsaicin</keyword>
  <keyword>placebo</keyword>
  <keyword>trial</keyword>
  <keyword>diabetic polyneuropathy</keyword>
  <keyword>neuropathic pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetic Neuropathies</mesh_term>
    <mesh_term>Polyneuropathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capsaicin</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>April 24, 2017</submitted>
    <returned>August 2, 2017</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

